A directory of where to buy chemicals in the USA, including: distributors, industrial manufacturers, bulk supplies and wholesalers of raw ingredients & finished goods.
Search for products or services, then visit the suppliers website for prices or more information.
| Product | Description | |
|---|---|---|
| GSK143 | GSK143 is a selective SYK inhibitor, which abrogates survival signals in chronic lymphocytic leukaemia. Synonyms: 2-{[(3r,4r)-3-Aminotetrahydro-2h-Pyran-4-Yl]amino}-4-[(4-Methylphenyl)amino]pyrimidine-5-Carboxamide. CAS No. 1240390-27-5. Molecular formula: C17H22N6O2. Mole weight: 342.40. |  |
| GSK143 dihydrochloride | GSK143 dihydrochloride is a highly selective SYK inhibitor, which abrogates survival signals in chronic lymphocytic leukaemia. Synonyms: GSK143 (dihydrochloride). Grade: 98%. CAS No. 2341796-81-2. Molecular formula: C17H24Cl2N6O2. Mole weight: 415.32. | |
| GSK143 dihydrochloride | GSK143 dihydrochloride is an orally active and highly selective spleen tyrosine kinase (SYK) inhibitor with a pIC50 of 7.5. GSK143 dihydrochloride inhibits phosphorylated Erk (pErk: pIC50=7.1)[1]. GSK143 dihydrochloride reduces inflammation and prevents recruitment of immune cells in the intestinal muscularis in mice[2][3]. Uses: Scientific research. Category: Signaling pathways. CAS No. 2341796-81-2. Pack Sizes: 10 mM * 1 mL in DMSO; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-12736A. |  |
| GSK-1440115 | GSK-1440115 is an orally active urotensin II receptor antagonist. It is used for the treatment of asthma. Uses: Gsk-1440115 is used for the treatment of asthma. Synonyms: GSK 1440115; GSK-1440115; GSK1440115. 4'-(1-(((6,7-Dichloro-3-oxo-2,3-dihydro-4H-1,4-benzoxazin-4-yl)acetyl)(methyl)amino)-2-(4-morpholinyl)ethyl)-4-diphenylcarboxylic acid; 4-[4-[(1R)-1-[[2-(6,7-dichloro-3-oxo-1,4-benzoxazin-4-yl)acetyl]-methylamino]-2-morpholin-4-ylethyl]phenyl]benzoic acid. Grade: >98 %. CAS No. 1003878-16-7. Molecular formula: C30H29Cl2N3O6. Mole weight: 598.47. | |
| GSK-1482160 | GSK-1482160 is an orally active and blood-brain barrier penetrant P2X7 receptor (P2X7R) negative allosteric modulator with pIC50s of 8.5 (human) and 6.5 (rat). GSK-1482160 reduces the efficacy of ATP at the P2X7 receptor without affecting its affinity, thereby inhibiting the release of IL-1β. GSK-1482160 is an effective radioligand and can be labeled with radioactive isotopes like 11C or 18F to image P2X7R. GSK-1482160 can be used for the studies of chronic joint pain and chronic constriction injury (CCI)[1][2][3]. Uses: Scientific research. Category: Signaling pathways. CAS No. 1001389-72-5. Pack Sizes: 10 mM * 1 mL in DMSO; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-19888. | |
| GSK-1520489A | GSK-1520489A is a PKMYT1 (active protein kinase) inhibitor (IC50=115 nM, Ki=10.94 nM)[1]. Uses: Scientific research. Category: Signaling pathways. CAS No. 1042433-41-9. Pack Sizes: 10 mM * 1 mL in DMSO; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-147312. | |
| GSK1521498 | GSK-1521498 is a novel μ-Opioid receptor antagonist. It shows to attenuate reward-driven compulsive behaviours, such as stimulant drug seeking or binge eating in animals and humans. It is mainly used for the treatment of obesity and alcohol dependence. It was developed by GlaxoSmithKline and in clinic phase 2. Uses: Gsk-1521498 is mainly used for the treatment of obesity and alcohol dependence. Synonyms: GSK-1521498; GSK1521498; GSK 1521498; GSK-1521498B; N-[[2,6-difluoro-4-[3-(1H-1,2,4-triazol-5-yl)phenyl]phenyl]methyl]-2,3-dihydro-1H-inden-2-amine; N-((3,5-difluoro-3'-(1H-1,2,4-triazol-3-yl)-[1,1'-biphenyl]-4-yl)methyl)-2,3-dihydro-1H-inden-2-amine. Grade: >98 %. CAS No. 1007573-18-3. Molecular formula: C24H20F2N4. Mole weight: 402.44. | |
| GSK1521498 free base | GSK1521498 free base is a potent and selective μ-opioid receptor (MOR) antagonist. GSK1521498 free base has the potential for disorders of compulsive consumption of food, alcohol, and agents[1]. Uses: Scientific research. Category: Signaling pathways. CAS No. 1007573-18-3. Pack Sizes: 10 mM * 1 mL in DMSO; 5 mg; 10 mg; 50 mg; 100 mg. Product ID: HY-115066. | |
| GSK1521498 free base (hydrochloride) | GSK1521498 free base (hydrochloride) is a selective μ-opioid receptor (MOR) antagonist. It is being used for the treatment of disorders of compulsive consumption of food, alcohol, and drugs. Synonyms: GSK1521498 hydrochloride. CAS No. 1007578-24-6. Molecular formula: C24H21ClF2N4. Mole weight: 438.90. | |
| GSK 1562590 hydrochloride | GSK 1562590 hydrochloride is a high affinity and selective urotensin II (UT) receptor antagonist (pKi = 9.14, 9.28, 9.34, 9.64 and 9.66 at monkey, human, mouse, cat and rat recombinant receptors, respectively). It displays selectivity for UT receptors over a range of GPCRs, ion channels, enzymes and neurotransmitter transporters. GSK 1562590 has been shown to inhibit human urotensin-II (hU-II)-induced contraction of isolated rat aorta in vitro and ex vivo. Synonyms: GSK 1562590 hydrochloride; GSK1562590 hydrochloride; GSK-1562590 hydrochloride; N-[(1R)-1-[3'-(Aminocarbonyl)[1,1'-biphenyl]-4-yl]-2-(1-pyrrolidinyl)ethyl]-6,7-dichloro-2,3-dihydro-N-methyl-3-oxo-4H-1,4-benzoxazine-4-acetamide hydrochloride; 3-[4-[(1R)-1-[[2-(6,7-dichloro-3-oxo-1,4-benzoxazin-4-yl)acetyl]-methylamino]-2-pyrrolidin-1-ylethyl]phenyl]benzamide hydrochloride. Grade: ≥98% by HPLC. CAS No. 1003878-07-6. Molecular formula: C30H30Cl2N4O4.HCl. Mole weight: 617.95. | |
| GSK163090 | GSK163090 is Potent, selective, and orally active 5-HT1A/B/D receptor antagonist. Synonyms: 1-(3-(2-(4-(2-methylquinolin-5-yl)piperazin-1-yl)ethyl)phenyl)imidazolidin-2-one; GSK163090; GSK-163090; GSK 163090. Grade: 98%. CAS No. 844903-58-8. Molecular formula: C25H29N5O. Mole weight: 415.54. | |
| GSK1702934A | GSK1702934A is a selective TRPC3 agonist. GSK1702934A modulates cardiac contractility and f arrhythmogenesis by activation of TRPC3[1][2]. Uses: Scientific research. Category: Signaling pathways. CAS No. 924377-85-5. Pack Sizes: 10 mM * 1 mL in DMSO; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-111098. | |
| GSK 1702934A | GSK 1702934A is a potent and selective TRPC3/6 activator (EC50 = 80 and 440 nM for TRPC3 and 6, respectively). However, it exhibits no activity at TRPV4, TRPA1, M1, M4, CaV1.2, hERG, NaV1.5, or CXCR5 receptors at concentrations <10 μM. Synonyms: 1,3-Dihydro-1-[1-[(5,6,7,8-tetrahydro-4H-cyclohepta[b]thien-2-yl)carbonyl]-4-piperidinyl]-2H-benzimidazol-2-one; 3-[1-(5,6,7,8-tetrahydro-4H-cyclohepta[b]thiophene-2-carbonyl)piperidin-4-yl]-1H-benzimidazol-2-one; GSK-2934A. Grade: ≥98% by HPLC. CAS No. 924377-85-5. Molecular formula: C22H25N3O2S. Mole weight: 395.52. | |
| GSK172981 | This molecular is a novel non-peptide tachykinin NK3 receptor antagonist and it has a very high affinity for native guinea pig (pK(I) value 7.8) tachykinin NK(3) receptors and recombinant human (pK(I) value 7.7). Meanwhile, GSK172981 also exhibited a competitive profile in antagonizing neurokinin B-stimulated neuronal activity recorded from the guinea pig medial habenula slices (apparent pK(B)=8.1). In the near future, this active molecular may be promising drug candidate in the treatment of schizophrenia. Uses: Treatment of schizophrenia. Synonyms: GSK172981; GSK-172981; GSK 172981. (S)-3-amino-N-(cyclopropyl(phenyl)methyl)-2-(3-fluorophenyl)quinoline-4-carboxamide. Grade: 98%. CAS No. 1133705-99-3. Molecular formula: C26H22FN3O. Mole weight: 411.48. | |
| GSK1795091 | GSK1795091 (CRX-601), an immunologic stimulator, is a synthetic TLR4 agonist. Antitumor activity. GSK1795091 can be used as a vaccine adjuvant to enhance both mucosal and systemic immunity to influenza virus vaccines. Not only, GSK1795091 inhibits tumor growth and increases the survival in mice model, but results in long term survival in influenza challenge model in mice[1][2][3]. Uses: Scientific research. Category: Signaling pathways. Alternative Names: CRX-601. CAS No. 1233589-81-5. Pack Sizes: 1 mg; 5 mg; 10 mg; 25 mg; 50 mg. Product ID: HY-111792. | |
| GSK180 | GSK180 is a selective, competitive, and potent inhibitor of kynurenine-3-monooxygenase (KMO), a key enzyme of tryptophan metabolism (IC50, ~6 nM), but shows negligible activity against other enzymes on the tryptophan pathway. GSK180 rapidly changes levels of kynurenine pathway metabolites, and acts as a useful tool to probe the therapeutic potential of KMO inhibition[1]. Uses: Scientific research. Category: Signaling pathways. CAS No. 1799725-26-0. Pack Sizes: 10 mM * 1 mL in DMSO; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-112179. | |
| GSK180736A | GSK180736A is a potent and selective inhibitor of GRK2 (IC50 = 0.77 μM) and ROCK1 (IC50 = 14 nM). Synonyms: GSK-180736A; 4-(4-fluorophenyl)-N-(1H-indazol-5-yl)-6-methyl-2-oxo-3,4-dihydro-1H-pyrimidine-5-carboxamide. Grade: >98%. CAS No. 817194-38-0. Molecular formula: C19H16FN5O2. Mole weight: 365.37. | |
| GSK1838705A | GSK1838705A is a small-molecule kinase inhibitor that inhibits IGF-IR and IR (insulin receptor) with IC50s of 2.0 and 1.6 nM, respectively. GSK1838705A blocks the in vitro proliferation of cell lines derived from solid and hematologic malignancies, including multiple myeloma and Ewing's sarcoma, and retards the growth of human tumor xenografts in vivo. Despite the inhibitory effect of GSK1838705A on insulin receptor, minimal effects on glucose homeostasis were observed at efficacious doses. GSK1838705A also inhibits the anaplastic lymphoma kinase (ALK), which drives the aberrant growth of anaplastic large-cell lymphomas, some neuroblastomas, and a subset of non-small cell lung cancers. GSK1838705A inhibits ALK, with an IC(50) of 0.5 nmol/L, and causes complete regression of ALK-dependent tumors in vivo at well-tolerated doses. GSK1838705A is therefore a promising antitumor agent for therapeutic use in human cancers. Synonyms: GSK1838705A; GSK-1838705A; GSK-1838705A. Grade: 0.98. CAS No. 1116235-97-2. Molecular formula: C27H29FN8O3. Mole weight: 532.57. | |
| GSK1842799 | GSK1842799 is a selective S1P1 receptor agonist for multiple sclerosis. It showed subnanomole S1P1 agonist activity with >1000× selectivity over S1P3 upon phosphorylation. It has good oral bioavailability. It was selected as a candidate for further clinical on the basis of the favorable in vitro ADME and in vivo PK/PD properties as well as broad toxicology evaluations. Uses: Gsk1842799 was selected as a candidate for further clinical. Synonyms: (S)-2-amino-2-(5-(4-(octyloxy)-3-(trifluoromethyl)phenyl)-1,3,4-thiadiazol-2-yl)propan-1-ol; GSK1842799; GSK 1842799; GSK 1842799. Grade: >98 %. CAS No. 1005407-76-0. Molecular formula: C20H28F3N3O2S. Mole weight: 431.52. | |
| GSK 189254A | GSK-189,254 is a H3 histamine receptor inverse agonist. It has subnanomolar affinity for the H3 receptor with Ki of 0.2nM. It possesses stimulant and nootropic effects and analgesic action suggesting a role for H3 receptors in pain processing in the spinal cord. No development was reported about Phase-II clinical trials for Narcolepsy in Europe. Uses: Narcolepsy. Synonyms: 6-((3-Cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy)-N-methyl-3-Pyridinecarboxamide. Grade: 98%. CAS No. 720690-73-3. Molecular formula: C21H25N3O2. Mole weight: 351.44. | |
| GSK-189254 hydrochloride | GSK-189,254 is a potent and selective H3-receptor inverse agonist developed by GlaxoSmithKline. It has subnanomolar affinity for the H3 receptor (Ki 0.2nM) and selectivity of over 10,000x for H3 over other histamine receptor subtypes.Animal studies have shown it to possess not only stimulant and nootropic effects, but also analgesic action suggesting a role for H3 receptors in pain processing in the spinal cord. GSK-189,254 and several other related drugs are currently being investigated as a treatment for Alzheimer's disease and other forms of dementia, as well as possible use in the treatment of conditions such as narcolepsy, or neuropathic pain which do not respond well to conventional analgesic drugs. Synonyms: GSK189254; GSK-189254; GSK-189,254. CAS No. 945493-87-8. Molecular formula: C21H26ClN3O2. Mole weight: 387.91. | |
| GSK-1904529a | GSK-1904529A is an IGF-1R Inhibitor, is is a promising candidate for therapeutic use in IGF-IR-dependent tumors. GSK1904529A selectively inhibits IGF-IR and IR with IC50s of 27 and 25 nmol/L, respectively. GSK1904529A blocks receptor autophosphorylation and downstream signaling, leading to cell cycle arrest. It inhibits the proliferation of cell lines derived from solid and hematologic malignancies, with multiple myeloma and Ewing's sarcoma cell lines being most sensitive. Oral administration of GSK1904529A decreases the growth of human tumor xenografts in mice, consistent with a reduction of IGF-IR phosphorylation in tumors. Despite the potent inhibitory activity of GSK1904529A on IR in vitro and in vivo, minimal effects on blood glucose levels are observed in animals at doses that show significant antitumor activity. Synonyms: GSK 4529; GSK4529; GSK-4529; GSK1904529a; GSK 1904529; GSK-1904529a. CAS No. 1089283-49-7. Molecular formula: C44H47F2N9O5S. Mole weight: 851.975. | |
| GSK1904529A | GSK1904529A is a potent, selective, orally active, and ATP-competitive inhibitor of insulin-like growth factor-1 receptor (IGF-1R) and insulin receptor (IR), with IC50s of 27 and 25 nM, respectively. GSK1904529A shows poor activity (IC50>1 μM) in 45 other serine/threonine and tyrosine kinases. GSK1904529A exhibits anti-tumor activity[1][2]. Uses: Scientific research. Category: Signaling pathways. CAS No. 1089283-49-7. Pack Sizes: 10 mM * 1 mL in DMSO; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-10524. | |
| GSK199 | GSK199 is an orally active, reversible, and selective PAD4 inhibitor with an IC50 of 200 nM in the absence of calcium. GSK199 can be used for the research of rheumatoid arthritis[1]. Uses: Scientific research. Category: Signaling pathways. CAS No. 1549811-53-1. Pack Sizes: 10 mM * 1 mL in DMSO; 1 mg; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-103058. | |
| GSK1997132B | PPARγ is a ligand-activated nuclear receptor and was reported to plays a role in energy metabolism, glucose homeostasis and microglia-mediated neuroinflammation. GSK1997132B is a metabolically stable, highly potent centrally penetrant PPARγ partial agonist. Synonyms: GSK 1997132B; GSK-1997132B; GSK1997132B; GSK1997132; GSK-1997132; GSK 1997132. (R)-1-((3,5-difluoropyridin-2-yl)methyl)-2-methyl-N-(1-phenylpropyl)-1H-benzo[d]imidazole-5-carboxamide. Grade: 98%. CAS No. 1168138-37-1. Molecular formula: C24H22F2N4O. Mole weight: 420.46. | |
| GSK199 hydrochloride | GSK199 is a potent and reversible inhibitor of PAD4 with an IC50 value of 200 nM) which is less potent than the related PAD4 inhibitor GSK484 (IC50 = 50 nM). Synonyms: [(3R)-3-amino-1-piperidinyl][2-(1-ethyl-1H-pyrrolo[2,3-b]pyridin-2-yl)-7-methoxy-1-methyl-1H-benzimidazol-5-yl]-methanone, monohydrochloride. Grade: ≥98%. CAS No. 1549811-53-1. Molecular formula: C24H28N6O2·HCl. Mole weight: 469. | |
| GSK-2018682 | GSK-2018682 is a potent and selective agonist of sphingosine-1-phosphate receptor (S1PR) subtype 1 that has the potential to treat multiple sclerosis (MS). Synonyms: GSK2018682; GSK 2018682; GSK-2018682. UNII-NJL503AIJA; NJL503AIJA; 4-(4-(5-(5-chloro-6-isopropoxypyridin-3-yl)-1,2,4-oxadiazol-3-yl)-1H-indol-1-yl)butanoic acid. Grade: ≥98%. CAS No. 1034688-30-6. Molecular formula: C22H21ClN4O4. Mole weight: 440.884. | |
| GSK2033 | GSK2033 is a LXR antagonist with pIC50s of 7 and 7.4 for LXRα or LXRβ, respectively. Uses: Scientific research. Category: Signaling pathways. CAS No. 1221277-90-2. Pack Sizes: 10 mM * 1 mL in DMSO; 1 mg; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-108688. | |
| GSK-2033 | This active molecular is a cell permeable, potent LXR (liver-X-receptor) antagonist. pIC50 values is 7.0 for LXRα and 7.4 for LXRβ. GSK2033 enhances T-cell proliferation and Th1/Th2/Th17 differentiation when treatment of murine CD41 T cells. Synonyms: GSK-2033; GSK2033; GSK 2033; CHEMBL1093266; GTPL8690; SCHEMBL13280409; 2,4,6-trimethyl-N-[[4-(3-methylsulfonylphenyl)phenyl]methyl]-N-[[5-(trifluoromethyl)furan-2-yl]methyl]benzenesulfonamide. Grade: 98%. CAS No. 1221277-90-2. Molecular formula: C29H28F3NO5S2. Mole weight: 591.66. | |
| GSK205 | GSK205 is a potent and selective antagonist of TRPV4 with an IC50 of 4.19 μM for inhibiting TRPV4-mediated Ca2+ influx. Synonyms: N-(4-(2-(benzyl(methyl)amino)ethyl)phenyl)-5-(pyridin-3-yl)thiazol-2-amine hydrobromide; N-(4-{2-[Benzyl(methyl)amino]ethyl}phenyl)-5-(3-pyridinyl)-1,3-thiazol-2-amine hydrobromide (1:1); 2-Thiazolamine, N-[4-[2-[methyl(phenylmethyl)amino]ethyl]phenyl]-5-(3-pyridinyl)-, hydrobromide (1:1). Grade: ≥98%. CAS No. 1263068-83-2. Molecular formula: C24H25BrN4S. Mole weight: 481.45. | |
| GSK205 | GSK205 is a potent, selective TRPV4 antagonist with an IC50 of 4.19? μM for inhibiting TRPV4-mediated Ca2+ influx[1][2]. Uses: Scientific research. Category: Signaling pathways. CAS No. 1263068-83-2. Pack Sizes: 10 mM * 1 mL in DMSO; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-120691A. | |
| GSK2110183 | GSK2110183 is an orally bioavailable pan-Akt inhibitor with IC50s of 0.08/2/2.6 nM for Akt1/Akt2/Akt3 respectively. Synonyms: GSK2110183; GSK 2110183; GSK-2110183. Grade: >98%. CAS No. 1047634-63-8. Molecular formula: C18H16Cl2F2N4OS. Mole weight: 445.31. | |
| GSK2110183 hydrochloride | GSK2110183 is an orally bioavailable pan-Akt inhibitor with IC50s of 0.08/2/2.6 nM for Akt1/Akt2/Akt3 respectively. Synonyms: Afuresertib-F HCl; GSK2110183 analog 1 (hydrochloride). Grade: 99%. CAS No. 2070009-64-0. Molecular formula: C18H17Cl3F2N4OS. Mole weight: 481.77. | |
| GSK2141795 hydrochloride | GSK2141795 Hcl is a potent and selective pan-Akt inhibitor with IC50s of 180/328/38 nM for Akt1/Akt2/Akt3 respectively. Synonyms: GSK-2141795 Hydrochloride; GSK 2141795 Hydrochloride; GSK2141795 Hydrochloride; GSK2141795 HCl; Uprosertib. Grade: >98%. CAS No. 1047635-80-2. Molecular formula: C18H17Cl3F2N4O2. Mole weight: 465.71. | |
| GSK215 | GSK215, a potent and selective PROTAC focal adhesion kinase (FAK) degrader, is designed by a binder for the VHL E3 ligase and the FAK inhibitor VS-4718. It induces rapid and prolonged degradation of FAK, with a long-lasting effect on FAK levels and a significant disconnect in pharmacokinetic/pharmacodynamics (PK/PD). Synonyms: (2S,4R)-4-Hydroxy-1-((S)-2-(2-(4-(3-methoxy-4-((4-((2-(methylcarbamoyl)phenyl)amino)-5-(trifluoromethyl)pyridin-2-yl)amino)phenyl)piperazin-1-yl)acetamido)-3,3-dimethylbutanoyl)-N-((S)-1-(4-(4-methylthiazol-5-yl)phenyl)ethyl)pyrrolidine-2-carboxamide. Grade: ≥95%. CAS No. 2743427-26-9. Molecular formula: C50H59F3N10O6S. Mole weight: 985.13. | |
| GSK215 | GSK215 is a potent and selective PROTAC focal adhesion kinase (FAK) degrader with a pDC50 of 8.4. GSK215 is designed by a binder for the VHL E3 ligase and the FAK inhibitor VS-4718. GSK215 induces rapid and prolonged FAK degradation, giving a long-lasting effect on FAK levels and a marked pharmacokinetic/pharmacodynamics (PK/PD) disconnect[1]. Uses: Scientific research. Category: Signaling pathways. CAS No. 2743427-26-9. Pack Sizes: 10 mM * 1 mL in DMSO; 5 mg; 10 mg; 25 mg. Product ID: HY-132296. | |
| GSK215083 | GSK215083 is a PET radioligand for the 5-hydroxytrypamine-6 (5HT6) receptor. It is a quinoline based compounds that acts by antagonising the 5-HT6 receptor. It binds to receptors 5HT6 in the striatum and 5-hydroxytryptamine-2A (5HT2A) in the frontal cortex. It is used for the treatment of Alzheimer's disease and used as a PET ligand for identification of occupancy of the 5HT6 receptor coupled with 11C. Uses: Gsk215083 is used for the treatment of alzheimer's disease and used as a pet ligand for identification of occupancy of the 5ht6 receptor coupled with 11c. Synonyms: GSK-215083; GSK 215083; GSK215083; 3-(3-Fluoro-benzenesulfonyl)-8-(4-Methyl-piperazin-1-yl)-quinoline; GSK-215083; Quinoline, 3-((3-fluorophenyl)sulfonyl)-8-(4-methyl-1-piperazinyl)-. Grade: 98%. CAS No. 607742-80-3. Molecular formula: C20H20FN3O2S. Mole weight: 385.46. | |
| GSK2190915 | GSK2190915 is a potent FLAP(5-Lipoxygenase-activating protein) inhibitor. It exhibits excellent preclinical toxicology and pharmacokinetics in rat and dog. It also demonstrated an extended pharmacodynamic effect in a rodent bronchoalveolar lavage (BAL) model. It increased survival time in mice exposed to a lethal intravenous injection of platelet activating factor (PAF). Synonyms: AM-803; AM 803; AM803; 3Fiboflapon; GSK2190915; GSK 2190915; GSK-2190915. Grade: >98%. CAS No. 936350-00-4. Molecular formula: C38H43N3O4S. Mole weight: 637.83. | |
| GSK2190915 sodium salt | GSK2190915(AM-803; Fiboflapon) sodium salt is a potent FLAP(5-Lipoxygenase-activating protein) inhibitor with binding IC50 of 2.9 nM. Synonyms: GSK2190915 sodium salt; GSK 2190915 sodium salt; GSK-2190915 sodium salt; GSK-2190915A; GSK 2190915A; GSK2190915A; Fiboflapon sodium; AM-803 sodium; AM 803 sodium; AM803 sodium. Grade: >98%. CAS No. 1196070-26-4. Molecular formula: C38H42N3NaO4S. Mole weight: 659.81. | |
| GSK2193874 | GSK2193874 is a potent, orally active and specific antagonist of TRPV4 ion channels (IC50 values 2 and 40 nM for rat and human receptors, respectively). GSK2193874 is selective over a panel of ~200 human receptors, channels and enzymes. Synonyms: GSK2193874; GSK 2193874; GSK-2193874; GSK2193874A; GSK 2193874A; GSK-2193874A; 7-bromo-N-(1-phenylcyclopropyl)-3-[(4-piperidin-1-ylpiperidin-1-yl) methyl]-2-[3-(trifluoromethyl)phenyl]quinoline-4-carboxamide. CAS No. 1336960-13-4. Molecular formula: C37H38BrF3N4O. Mole weight: 691.62. | |
| GSK2193874 | GSK2193874 is an orally active, potent, and selective TRPV4 antagonist with IC50s of 2 nM and 40 nM for rTRPV4 and hTRPV4[1]. Uses: Scientific research. Category: Signaling pathways. CAS No. 1336960-13-4. Pack Sizes: 10 mM * 1 mL in DMSO; 2 mg; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-100720. | |
| GSK2194069 | GSK2194069 is a fatty acid synthase (FAS) inhibitor. GSK2194069 is a potent and specific inhibitor of the β-ketoacyl reductase (KR) activity of hFAS with an IC50 of 7.7 ± 4.1 nM for the overall hFAS reaction. FAS is upregulated in some cancers, including prostate cancer. GSK2194069 was found to inhibit tumour growth in prostate cancer C42b cell xenografts generated in Nod-SCID-gamma mice. Cellular FAS inhibition reduced cell growth were also demonstrated in non-small-cell lung (A549) cancer cell lines with an average EC50 of 15 ± 0.5 nM. Synonyms: GSK 2194069; GSK-2194069. Grade: >98%. CAS No. 1332331-08-4. Molecular formula: C25H24N4O3. Mole weight: 428.48. | |
| GSK2194069 | GSK2194069 is a potent inhibitor of β-ketoyl reductase (KR) of fatty acid synthase (FASN), with an IC50 value of 7.7 nM. GSK2194069 shows specifically inhibitory effect on FAS expressing cancer cells, by acting potent efficacy on acetoacetyl-CoA, NADPH with IC50 or Ki values of 4.8 nM and 5.6 nM, respectively[1][2][3]. Uses: Scientific research. Category: Signaling pathways. CAS No. 1332331-08-4. Pack Sizes: 10 mM * 1 mL in DMSO; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-12325. | |
| GSK2200150A | GSK2200150A, identified by high-throughput screening (HTS) campaign, is an anti-tuberculosis (TB) agent. It is a novel antimycobacterial agent against Mycobacterium tuberculosis. Synonyms: GSK-2200150A. Grade: 95%. CAS No. 1443138-53-1. Molecular formula: C20H23NO3S. Mole weight: 357.47. | |
| GSK2239633A | GSK2239633A is a CC-chemokine receptor 4 (CCR4) antagonist, which inhibits the binding of [125I]-TARC to human CCR4 with a pIC50 of 7.96. Uses: Scientific research. Category: Signaling pathways. CAS No. 1240516-71-5. Pack Sizes: 10 mM * 1 mL in DMSO; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-100183. | |
| GSK2245035 | This active molecular is a selective TLR7 (Toll-like receptor 7) agonist with preferential Type-1 IFN-stimulating properties which is under development of GlaxoSmithKline. GSK2245035 displays potent IFNα inducing potency and IFNα/TNFα selectivity. In Aug 2015, GlaxoSmithKline completed a phase II follow-up trial for Allergic asthma and Allergic rhinitis in Canada. In Jul 2016, GlaxoSmithKline planed a phase II trial for Allergic asthma in Germany (Intranasal). Uses: Allergic asthma; allergic rhinitis. Synonyms: GSK2245035; GSK 2245035; GSK-2245035; (S)-6-amino-2-(pentan-2-yloxy)-9-(5-(piperidin-1-yl)pentyl)-7,9-dihydro-8H-purin-8-one; 1325212-97-2 (maleate salt). Grade: 98%. CAS No. 1207629-49-9. Molecular formula: C20H34N6O2. Mole weight: 390.52. | |
| GSK 2250665A | GSK 2250665A is an Itk inhibitor (pKi = 9.2) displaying selectivity for Itk over Aurora B kinase and Btk (pIC50 = 6.4 and 6.5, respectively) and a panel of other kinases. GSK 2250665A was shown to inhibit IFNγ production in PBMCs. Synonyms: GSK-2250665A; GSK 2250665A; GSK2250665A; GSK-2250665; GSK 2250665; GSK2250665; trans-4-[[4-[(6-Ethyl-2-benzothiazolyl)amino]-6-(phenylmethyl)-2-pyrimidinyl]amino]cyclohexanol. Grade: ≥97% by HPLC. CAS No. 1246030-96-5. Molecular formula: C26H29N5OS. Mole weight: 459.61. | |
| GSK2256098 | GSK2256098 is a selective FAK kinase inhibitor, which inhibits growth and survival of pancreatic ductal adenocarcinoma cells. Uses: Scientific research. Category: Signaling pathways. CAS No. 1224887-10-8. Pack Sizes: 10 mM * 1 mL in DMSO; 2 mg; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-100498. | |
| GSK-2256098 | GSK2256098, also known as GTPL7939, is a focal adhesion kinase-1 (FAK) inhibitor with potential antiangiogenic and antineoplastic activities. Synonyms: GSK2256098; GSK 2256098; GSK-2256098; GTPL7939; GTPL-7939; GTP L7939. Grade: 98%. CAS No. 1224887-10-8. Molecular formula: C20H23ClN6O2. Mole weight: 414.89. | |
| GSK2256294A | GSK2256294A, an effective inhibitor of human soluble epoxide hydrolase(sEH), was developed by GSK and still under Phase I trial in Chronic obstructive pulmonary disease. IC50: 27pM. Uses: Gsk2256294a is an effective inhibitor of human soluble epoxide hydrolase(seh). Synonyms: GSK2256294; GSK-2256294; GSK 2256294; GSK-2256294A; GSK 2256294A. Grade: 98%. CAS No. 1142090-23-0. Molecular formula: C21H24F3N7O. Mole weight: 447.46. | |
| GSK2256294A | GSK2256294A (GSK 2256294) is a selective and orally active inhibitor of soluble epoxide hydrolase (sEH). GSK2256294A inhibits recombinant human sEH, rat sEH orthologs and murine sEH orthologs with IC50s of 27, 61 and 189 pM, respectively. GSK2256294A can be used for the research of chronic obstructive pulmonary disease (COPD) and cardiovascular disease[1]. Uses: Scientific research. Category: Signaling pathways. Alternative Names: GSK 2256294. CAS No. 1142090-23-0. Pack Sizes: 10 mM * 1 mL in DMSO; 1 mg; 5 mg; 10 mg; 50 mg; 100 mg. Product ID: HY-19644. | |
| GSK-2262167 hydrate | GSK-2262167 is a potent S1P3-sparing and S1P1 agonist and has a potent activity is in a collagen-induced arthritis model as efficacious as fingolimod and shows excellent pharmacokinetic properties preclinically. Uses: Arthritis. Synonyms: GSK-2262167 sodium; GSK 2262167 sodium; GSK2262167 sodium; sodium 3-(6-(5-(3-cyano-4-isopropoxyphenyl)-1,2,4-oxadiazol-3-yl)-5-methyl-3,4-dihydroisoquinolin-2(1H)-yl)propanoate. Grade: ≥98%. CAS No. 1458576-13-0. Molecular formula: C25H28N4O5. Mole weight: 464.51. | |
| GSK-2262167 sodium | This molecular is a potent S1P3-sparing and S1P1 agonist. Meanwhile GSK-2262167 has a potent activity is in a collagen-induced arthritis model as efficacious as fingolimod and shows excellent pharmacokinetic properties preclinically. Uses: Arthritis. Synonyms: GSK-2262167 sodium; GSK 2262167 sodium; GSK2262167 sodium; sodium 3-(6-(5-(3-cyano-4-isopropoxyphenyl)-1,2,4-oxadiazol-3-yl)-5-methyl-3,4-dihydroisoquinolin-2(1H)-yl)propanoate,1165924-28-6 (free acid); 458576-13-0 (hydrate). Grade: 98%. CAS No. 1165923-54-5. Molecular formula: C25H25N4NaO4. Mole weight: 468.49. | |
| GSK2269557 | GSK2269557, an effective PI3K inhibitor, could be used as against inflammatory and some autoimmune diseases. It has just completes a phase II trial against Asthma. Uses: Gsk2269557 is an effective pi3k inhibitor that could be used as against inflammatory and some autoimmune diseases. Synonyms: CHEMBL2216859; GSK2269557 (free base); GSK2269557; GSK-2269557; GSK 2269557; Nemiralisib; 2-(6-(1H-indol-4-yl)-1H-indazol-4-yl)-5-((4-isopropylpiperazin-1-yl)methyl)oxazole; 6-(1H-indol-4-yl)-4-(5-{[4-(1-methylethyl)-1-piperazinyl]methyl}-1,3-oxazol-2-yl)-1H-indazole. Grade: 95%. CAS No. 1254036-71-9. Molecular formula: C26H28N6O. Mole weight: 440.54. | |
| GSK-2269557 HCl salt | GSK-2269557 is a selective Phosphatidylinositol 3 kinase delta inhibitor originated by GlaxoSmithKline. GSK-2269557 is highly selective for PI3Kδ over the closely related isoforms and is active in a animal model of Th2-driven lung inflammation. Treatment for Asthma and Chronic obstructive pulmonary disease(COPD) is in clinical trials Phase II. Uses: Asthma; chronic obstructive pulmonary disease. Synonyms: GSK-2269557 HCl salt; GSK 2269557 HCl salt; GSK2269557 HCl salt; 6-(1H-indol-4-yl)?-4-[5-[[4-(1-methylethyl)?-1-piperazinyl]?methyl]?-2-oxazolyl]?-1H-indazole, monohydrochloride; 1254036-71-9(free base). Grade: 98%. CAS No. 1254036-77-5. Molecular formula: C26H28N6O; HCl. Mole weight: 477.01. | |
| GSK2292767 | GSK2292767 is a Phosphatidylinositol 3 kinase delta inhibitor applicated for the treatment of respiratory diseases including asthma and COPD in clinical trials. GSK2292767 is highly selective for PI3Kδ over the closely related isoforms and is really active in the animal model of Th2-driven lung inflammation. Uses: Asthma and copd. Synonyms: GSK2292767; GSK-2292767; GSK 2292767. N-[5-[4-[5-[[(2R,6S)-2,6-dimethylmorpholin-4-yl]methyl]-1,3-oxazol-2-yl]-1H-indazol-6-yl]-2-methoxypyridin-3-yl]methanesulfonamide; SCHEMBL173490; ZINC95938263; KB-78330; 1254036-66-2; Methanesulfonamide,N-[5-[4-[5-[[(2R,6S)-2,6-dimethyl-4-morpholinyl]methyl]-2-oxazolyl]-1H-indazol-6-yl]-2-methoxy-3-pyridinyl]. Grade: 98%. CAS No. 1254036-66-2. Molecular formula: C24H28N6O5S. Mole weight: 512.58. | |
| GSK2292767 | GSK2292767 is a potent and selective inhibitor of PI3Kδ, with a pIC50 of 10.1. GSK2292767 showing greater than 500-fold selective over the other PI3K isoforms. GSK2292767 can be used for the research of respiratory disease[1]. Uses: Scientific research. Category: Signaling pathways. CAS No. 1254036-66-2. Pack Sizes: 10 mM * 1 mL in DMSO; 5 mg; 10 mg; 25 mg. Product ID: HY-15280. | |
| GSK232 | GSK232, a highly selective, cellularly penetrant inhibitor of CECR2, has excellent physicochemical properties. Synonyms: (S)-N-(4-chloro-3-((3-cyclopropylpyrrolidin-1-yl)sulfonyl)phenyl)-2-(5-methyl-4,5,6,7-tetrahydro-1H-[1,2,3]triazolo[4,5-c]pyridin-1-yl)acetamide. CAS No. 2702984-69-6. Molecular formula: C21H27ClN6O3S. Mole weight: 479.00. | |
| GSK2330672 | GSK-2330672, an ASBT inhibitor, has been developed for the treatment of type 2 diabetes and is currently under Phase II trail against primary biliary cirrhosis and type 2 diabetes. IC50: 42 ± 3 nM. Uses: Gsk-2330672 is an asbt inhibitor that has been developed for the treatment of type 2 diabetes and is currently under phase ii trail against primary biliary cirrhosis and type 2 diabetes. Synonyms: CHEMBL2387408; UNII-386012Z45S; GSK2330672; GSK-2330672; SCHEMBL2586025; CZGVOBIGEBDYTP-VSGBNLITSA-N. Grade: 98%. CAS No. 1345982-69-5. Molecular formula: C28H38N2O7S. Mole weight: 546.68. | |
| GSK2332255B | GSK2332255B is a potent and selective antagonist of TRPC3 and TRPC6 with IC50s of 5 and 4 nM for rat TRPC3 and rat TRPC6, respectively. It exhibits ≥100-fold selectivity for TRPC3/6 over other calcium-permeable channels. Synonyms: (5-chloro-2-((6-fluorobenzo[d][1,3]dioxol-5-yl)amino)thiazol-4-yl)(2,3-dimethylpiperidin-1-yl)methanone; Methanone, [5-chloro-2-[(6-fluoro-1,3-benzodioxol-5-yl)amino]-4-thiazolyl](2,3-dimethyl-1-piperidinyl)-; GSK-255B. Grade: ≥90%. CAS No. 1366233-41-1. Molecular formula: C18H19ClFN3O3S. Mole weight: 411.88. | |
| GSK2334470 | GSK2334470 is a potent 3-phosphoinositide-dependent protein kinase (PDK1) inhibitor (IC50 ~ 10 nM), which does not suppress the activity of 93 other protein kinases including 13 AGC-kinases most related to PDK1 at 500-fold higher concentrations. GSK2334470 also inhibited T-loop phosphorylation and activation of Akt. GSK2334470 will be a useful tool for delineating the roles of PDK1 in biological processes. Synonyms: GSK2334470; GSK2334470; GSK2334470. Grade: 0.98. CAS No. 1227911-45-6. Molecular formula: C25H34N8O. Mole weight: 462.602. | |
| GSK2334470 | GSK2334470 is a highly specific and potent inhibitor of PDK1 with an IC50 of 10 nM. Uses: Scientific research. Category: Signaling pathways. CAS No. 1227911-45-6. Pack Sizes: 10 mM * 1 mL in DMSO; 5 mg; 10 mg; 50 mg; 100 mg. Product ID: HY-14981. | |
| GSK239512 | GSK239512 is a potent and brain penetrated H3 receptor antagonist. GSK239512 can be used for the research of mild-to-moderate Alzheimer's disease (AD)[1]. Uses: Scientific research. Category: Signaling pathways. CAS No. 720691-69-0. Pack Sizes: 10 mM * 1 mL in DMSO; 1 mg; 5 mg; 10 mg; 25 mg; 50 mg. Product ID: HY-106000. | |
| GSK-239512 | GSK-239512 is a histamine H3 receptor antagonist. In Jun 2015, Phase-II for Schizophrenia in USA was discontinued. Phase II clinical trilas for the treatment of Multiple sclerosis are on-going. Uses: Multiple sclerosis. Synonyms: GSK-239512; GSK239512; GSK 239512; 1-(6-((3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy)-3-pyridinyl)-2-Pyrrolidinone. Grade: 98%. CAS No. 720691-69-0. Molecular formula: C23H27N3O2. Mole weight: 377.48. | |
| GSK-25 | GSK-25 is a potent, selective and orally bioavailable ROCK1 inhibitor with an IC50 of 7 nM. GSK-25 maintains good selectivity against a panel of 31 kinases (>100 fold), as well as RSK1 and p70S6K (RSK1: IC50 = 398 nM, p70S6K: IC50 = 1 μM). Synonyms: GSK25; GSK 25; 5-Pyrimidinecarboxamide, 4-(4-chloro-2-fluorophenyl)-2-(2-chloro-4-pyridinyl)-N-(6-fluoro-1H-indazol-5-yl)-1,4-dihydro-6-Methyl-. Grade: 99%. CAS No. 874119-56-9. Molecular formula: C24H16Cl2F2N6O. Mole weight: 513.33. | |
| GSK251 | GSK251 is a potent and selective PI3Kδ inhibitor. Synonyms: GSK-251; GSK 251. Grade: 98% by HPLC. CAS No. 2125968-05-8. Molecular formula: C29H37FN6O4S. Mole weight: 584.7. | |
| GSK2556286 | GSK2556286 (GSK286) is an orally active and cholesterol-dependent Mycobacterium tuberculosis inhibitor. GSK2556286 inhibits Mycobacterium tuberculosis inside infected macrophages (IC50 = 0.07 μM in THP-1 cells), in the presence of cholesterol. GSK2556286 acts via Rv1625c, a membrane-bound adenylyl cyclase in Mycobacterium tuberculosis. GSK2556286 is an Rv1625 agonist leading to increased cAMP and reduced cholesterol metabolism. GSK2556286 can be studied in research for antitubercular purposes[1][2][3]. Uses: Scientific research. Category: Signaling pathways. Alternative Names: GSK286. CAS No. 1210456-20-4. Pack Sizes: 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-147017. | |
| GSK256066 | GSK256066 is a selective PDE4B(equal affinity to isoforms A-D) inhibitor with IC50 of 3.2 pM, >380,000-fold selectivity versus PDE1/2/3/5/6 and >2500-fold selectivity against PDE4B versus PDE7. Synonyms: GSK256066; GSK 256066; GSK-256066. Grade: >98%. CAS No. 801312-28-7. Molecular formula: C27H26N4O5S. Mole weight: 518.58. | |
| GSK256066 | GSK256066 is a selective and high-affinity phosphodiesterase 4 (PDE4) inhibitor, with an IC50 of 3.2 pM for PDE4B. GSK256066 is developed for the research of chronic obstructive pulmonary disease[1]. Uses: Scientific research. Category: Signaling pathways. CAS No. 801312-28-7. Pack Sizes: 10 mM * 1 mL in DMSO; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-10469. | |
| GSK256066 2,2,2-trifluoroacetic acid | GSK256066 is a selective PDE4B(equal affinity to isoforms A-D) inhibitor with IC50 of 3.2 pM, >380,000-fold selectivity versus PDE1/2/3/5/6 and >2500-fold selectivity against PDE4B versus PDE7. Synonyms: GSK-256066; GSK 256066. Grade: >98%. CAS No. 1415560-64-3. Molecular formula: C29H27F3N4O7S. Mole weight: 632.61. | |
Our database is helping our users find suppliers everyday.
